Sandoz
Sandoz, a division of Novartis, is a global leader in the pharmaceutical industry, headquartered in Switzerland (CH). Founded in 1886, Sandoz has established itself as a pioneer in generic and biosimilar medicines, focusing on high-quality, affordable healthcare solutions. With a strong presence in Europe, North America, and emerging markets, the company is dedicated to improving patient access to essential medications. Sandoz's core offerings include a diverse range of generic pharmaceuticals, biosimilars, and over-the-counter products, distinguished by their rigorous quality standards and innovative approaches. The company has achieved significant milestones, including the launch of several groundbreaking biosimilars, solidifying its position as a trusted partner in the healthcare sector. With a commitment to sustainability and patient-centric solutions, Sandoz continues to shape the future of medicine.
DitchCarbon Score
How does Sandoz's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sandoz's score of 61 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sandoz's reported carbon emissions
In 2023, Sandoz reported total carbon emissions of approximately 2,278,340,000 kg CO2e, with emissions distributed across various scopes: 86,200,000 kg CO2e (Scope 1), 122,300,000 kg CO2e (Scope 2), and a significant 2,051,700,000 kg CO2e (Scope 3). This represents a notable commitment to transparency in emissions reporting, particularly as they disclose all three scopes of emissions. In 2022, Sandoz's emissions were approximately 2,093,880,000 kg CO2e, with Scope 1 emissions at 79,940,000 kg CO2e and Scope 2 emissions at 151,480,000 kg CO2e. The increase in emissions from 2022 to 2023 highlights the challenges faced in reducing carbon footprints within the pharmaceutical sector. Sandoz has set near-term climate commitments, although specific reduction targets have not been disclosed. The company is actively engaged in climate initiatives, as indicated by its commitment status, but has not yet established a net-zero target. The organisation is headquartered in Switzerland and operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector, where it continues to explore strategies for emissions reduction and sustainability. Overall, Sandoz's emissions data reflects its ongoing efforts to address climate change while navigating the complexities of the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 75,620,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 158,430,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sandoz is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
